Will Weakness in GeneReach Biotechnology Corp.’s (GTSM:4171) Stock Prove Temporary Given Strong Fundamentals? – Simply Wall St

With its stock down 30% over the past three months, it is easy to disregard GeneReach Biotechnology (GTSM:4171). However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. Specifically, we decided to study GeneReach Biotechnology’s ROE in this article.

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. Put another way, it reveals the company’s success at turning shareholder investments into profits.

Check out our latest analysis for GeneReach Biotechnology

How To Calculate Return On Equity?

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity

So, based on the above formula, the ROE for GeneReach Biotechnology is:

27% = NT$206m ÷ NT$774m (Based on the trailing twelve months to September 2020).

The ‘return’ is the yearly profit. That means that for every NT$1 worth of shareholders’ equity, the company generated NT$0.27 in profit.

Why Is ROE Important For Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or “retains” for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don’t have the same features.

GeneReach Biotechnology’s Earnings Growth And 27% ROE

To begin with, GeneReach Biotechnology has a pretty high ROE which is interesting. Second, a comparison with the average ROE reported by the industry of 11% also doesn’t go unnoticed by us. So, the substantial 70% net income growth seen by GeneReach Biotechnology over the past five years isn’t overly surprising.

We then compared GeneReach Biotechnology’s net income growth with the industry and we’re pleased to see that the company’s growth figure is higher when compared with the industry which has a growth rate of 10% in the same period.

past-earnings-growth

GTSM:4171 Past Earnings Growth March 1st 2021

Earnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock’s future looks promising or ominous. Is GeneReach Biotechnology fairly valued compared to other companies? These 3 valuation measures might help you decide.

Is GeneReach Biotechnology Efficiently Re-investing Its Profits?

Conclusion

On the whole, we feel that GeneReach Biotechnology’s performance has been quite good. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Not to forget, share price outcomes are also dependent on the potential risks a company may face. So it is important for investors to be aware of the risks involved in the business. Our risks dashboard will have the 1 risk we have identified for GeneReach Biotechnology.

Promoted
If you decide to trade GeneReach Biotechnology, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Leave a Reply

Your email address will not be published. Required fields are marked *